Edmond de Rothschild Investment Partners acquires Allodiagnostic, the French leader in property diagnostics

Press release - 9/12/2017

Managed by the Edmond de Rothschild Investment Partners Small Caps team, CABESTAN Capital 2 has joined forces with the management team led by Edouard Carvallo for conducting Allodiagnostic’s exit from the Texa Group.

Allodiagnostic is the leading integrated network of property diagnostics in France. Founded in 2002, the company had been a wholly owned subsidiary since 2009 of the Texa Group. Texa is a leader in insurance appraisal services with €191m in turnover in 2016. With its nationwide network of 35 agencies and an online platform that naturally provides the best market referencing, Allodiagnostic performs over 400,000 diagnostics yearly for individuals and professionals.

As part of the support it provides and for securing building projects for sale, lease as well as for specific projects, the group offers a full range of diagnostics that covers surfaces, asbestos, lead, termites, electrical installations, gas, etc. Allodiagnostic is the only independent operator of technical control offices to offer the 3 major activities: transactions and rentals, asbestos and lead samples, as well as dust removal processes. At the cutting edge with its digital offer, the group is the only platform that offers the free choice of the diagnostician while facilitating the scheduling of appointments, estimates and online payment. With the addition of its air-sampling laboratory in 2016, Allodiagnostic has been accredited by the French accreditation committee (COFRAC) for conducting asbestos fibre removal operations.

Based in Château-Gontier in Mayenne, company turnover was over €20m in 2016 with 250 employees. The group intends to pursue the strong growth witnessed over the past few years while broadening the range of its diagnostics offer. It will thus be able to meet the growing demands arising from the standards concerning the property sector while reinforcing the online channel.

Alexandre Foulon, Associate Director at Edmond de Rothschild Investment Partners: “The Allodiagnostic buyout was a perfect fit for the support strategy of our highly committed management team within the context of this project that displays such a strong potential for organic and external growth alike.”

Edouard Carvallo, President and Co-Founder of Allodiagnostic: “We are delighted to have the support of Edmond de Rothschild Investment Partners in this adventure. Our goal is to strengthen our leadership position by pursuing the development of our offer and distribution channels, in particular with the recent launch of our marketplace.”

As part of the transaction, two regional directors, Jean de la Rousserie and Teva Sergent, have been appointed Assistant General Managers. Allodiagnostic is also pleased to welcome Charles de Cheffontaines (Centrale Marseille, IAE) as CEO. He had served prior as Director for 5 years with PWC Strategy&.

Financing for the transaction was completed with senior debt arranged by CIC Ouest, together with LCL and Crédit Agricole Anjou Maine.

 

For further information:  https://www.allodiagnostic.com/